Fri, Aug 22, 2014, 1:03 AM EDT - U.S. Markets open in 8 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Sep 21, 2013 1:47 PM Flag

    ECC 2013 Amsterdam

    $$$$
    I've spent a little time in the ECC site, and have concluded that the abstract embargo will be fully enforced till at least the 27th, but did find an "Abstracts not to be missed" link that gives some basic summaries for a few of the expected top contributions. Just figured to post this one as it hits close to home...

    "Abstract title: Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)
    Abstract number: 2861
    Speaker: Howard Scher, US"

    Exelixis has a presence in booth #4251, and I expect MMM's Friday presentation may include an intro to any key presentations that have been submitted.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      These three additional abstracts in the "not to be missed" GU-Prostate arena may provide some insights as to the future direction of the CRPC treatment landscape. I'm betting the Eleni Efstathiou presentation on combining ENZA & AA will gain considerable attention...

      "$ Abstract title: CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)
      Abstract number: 2850
      Speaker: Winald R. Gerritsen, NL
      $ Abstract title: An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
      Abstract number: 2853
      Speaker: Karim Fizazi, FR
      $ Abstract title: The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
      Abstract number: 2854
      Speaker: Eleni Efstathiou, US"

      GLTA

 
EXEL
4.09-0.02(-0.49%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.